I have really bad mental-health issues. The most important thing about my mental-health situation, I think, is how every single hour (it seems...I'm only being slightly hyperbolic) my consciousness changes to a new state. So there's extraordinary flux going on 24/7/365 in my consciousness.
1: Gut biota might underlie that flux; who knows, right?
2: We do in fact know that the gut biota are always in flux, correct? So maybe gut-biota flux underlies my consciousness flux.
3: What do you make of the below paper?
4: The paper gives a guide as to what someone with (e.g.) a bipolar diagnosis should do in order to improve their gut-biota situation, correct?
https://www.nature.com/articles/s41380-022-01456-3
This is the largest systematic literature review to date of gut microbiota composition across the major psychiatric conditions MDD, BD and SZ, comprising 56 comparison groups across 44 studies, and a total of 2510 psychiatric cases and 2407 controls. Our syntheses provide no strong evidence for a difference in the number or distribution of gut bacteria (α-diversity) in those with, compared to those without, a mental disorder. However, we did observe consistent differences in the overall composition of the gut microbiota (β-diversity) between cases and controls within each mental disorder category. In addition, we identified specific bacterial taxa with differential abundances between cases and controls, some of which were observed to be consistently different from controls across all three mental disorders. We identified substantial heterogeneity across studies in methodologies and reporting, including differences in study population inclusion and exclusion criteria, methods of gut microbiota stool sample collection, storage, processing and analysis, and consideration of, or adjustment for, key variables known to be associated with gut microbiota composition. Finally, we conducted a quality assessment of the included studies, the results of which highlight the need for guidelines on the conduct and reporting of microbiome-related research.
1: I thought that it was the case that very little lactate or lactic acid or whatever can actually cross the BBB. Do I have that correct? The paper talks about the dangers of lactate or lactic acid or whatever being produced, but I don't think that the paper ever says that this stuff crosses the BBB, though I could be confused.
2: Below is what the paper says about why the "bad" bacteria might be harmful:
https://www.nature.com/articles/s41380-022-01456-3
Our synthesis provided evidence of higher levels of lactic acid-producing bacteria across MDD, BD and SZ (Fig.
4). The genus
Lactobacillus was higher in cases across all three of the major mental disorders. Similarly, higher abundances of other lactic acid producers were reported across disorders, including higher
Enterococcus and
Streptococcus in MDD and BD, higher and
Escherichia/Shigella in MDD and SZ and higher
Bifidobacterium in BD. These bacteria are generally considered beneficial to the host and can regulate metabolism, protect from pathogenic invasion, and have immunomodulatory effects [
127,
128]. Lactic acid-producing bacteria also provide lactate for bacteria that use this molecule as a substrate to produce metabolites, such as the SCFA butyrate [
129], in a process known as ‘cross-feeding’. However, there are some circumstances in which lactate production and utilisation may be detrimental to host health. Accumulation of lactate in the gut is potentially deleterious and associated with acidosis, cardiac arrhythmia and neurotoxicity [
129,
130]. Many psychiatric disorders are associated with dysregulated mitochondrial energy generation, indexed by increased lactate and decreased pH (i.e. increased acidity) in the brain [
131]. Increased faecal lactate is also associated with GI diseases such as short bowel disease and ulcerative colitis, whereas faecal lactate is seldom detected under normal conditions [
129,
130]. Increased lactic acid production is a well described phenomenon in SZ and BD and is linked to mitochondrial dysfunction [
132]. Lactate is also able to cross the blood brain barrier [
133]; increased levels of lactic acid have been found in the brains of patients with MDD [
134], and higher brain lactate levels have been observed in post-mortem brains of people with BD and SZ [
131,
135]. We also observed higher abundances of bacterial genera that utilise lactate across studies, including
Megasphaera in BD and SZ, and
Escherichia/Shigella and
Veillonella in SZ and MDD, which may indicate a compensatory mechanism in response to increased lactate production. Thus, we speculate that increased abundances of lactic acid-producing bacteria, such as those observed in this review, may influence mental disorder pathophysiology via lactate accumulation.
However, it should be noted that lactate has alternative metabolic fates, which further highlights the complex nature of the gut microbiome ecosystem and cross-feeding. For example, this systematic review also identified consistently higher abundances of
Veillonella and
Megasphaera in mental disorders. Species within these genera metabolise lactate to the SCFAs propionate and acetate while producing hydrogen [
136]. Whilst propionate has been hypothesised to have antidepressant effects, excess propionate has been associated with increased depressive-like behaviours in animal studies [
137] and elevated levels of propionate have been reported in Alzheimer’s disease [
138]. In addition, it has been hypothesised that a by-product of lactate metabolism—hydrogen—may also influence host physiology [
130,
139]. Hydrogen cross-feeding can occur with sulphate-reducing bacteria (SRB), methanogenic archaea, and acetogenic bacteria, which respectively produce hydrogen sulphide, methane and acetate [
140]. Microorganisms that produce hydrogen sulphide (e.g.
Desulfosporosinus,
Desulfotomaculum,
Desulfovibrio) and methane (e.g.
Methanobrevibacter) have been reported to be in higher abundance in those with mental disorders [
70,
81,
97,
102,
106,
112]. Functional pathways associated with methanogenesis, methane metabolism, and methane oxidation, have also been reported as enriched in mental disorders [
66,
71,
95,
106]. Research investigating the influence of SRB and methanogens and their associated metabolites on health are inconsistent; both have been associated with both positive and negative health outcomes, but are hypothesised to be pro-inflammatory [
140,
141]. Future studies employing metabolomics, alongside gut microbiome composition and functional analyses, are required to further our understanding of the potential role of the gut microbiome and lactate metabolism pathways in mental disorder pathophysiology.
Our trans-diagnostic approach identified lower levels of the butyrate-producing bacteria
Coprococcus across all three mental disorders. Again, there was very little evidence to suggest this pattern was particularly associated with any specific disorder. Moreover, lower
Faecalibacterium was a shared feature of MDD and BD, and lower
Roseburia was a shared feature of BD and SZ; these bacteria are also butyrate producers. These findings are concordant with a Dutch study that identified
Faecalibacterium and
Coprococcus as positively correlated with quality-of-life scores in two large independent cohorts [
115].
Coprococcus was also identified as lower in participants with general practitioner- or self-reported depression, even when controlling for the use of anti-depressants [
115], which—like antipsychotics and anticonvulsants—have documented antimicrobial effects [
142]. Similarly, a large US study reported positive associations between
Coprococcus and
Faecalibacterium and a ‘health-related’ group of host factors [
143]. Lower
Roseburia levels have been observed in epilepsy and post-traumatic stress disorder, however inconsistent findings have been observed for autism spectrum disorder and Parkinson’s disease [
144]. Our findings are concordant with those observed across other mental disorders, which commonly report lower levels of faecal butyrate as well as reduced levels of butyrate-producing bacteria [
144].
The potential role of butyrate-producing bacteria has been extensively studied [
145,
146]. The production of butyrate and other SCFAs by host bacteria is primarily derived from the anaerobic fermentation of dietary fibre in the gut [
147]. However,
Roseburia species can produce butyrate via degradation of the mucin layer of the gut [
148]. Butyrate is a SCFA understood to confer health benefits predominantly through influencing the immune system and intestinal homeostasis [
149]. Butyrate is the primary source of energy for colon cells and plays an important role in maintaining gut barrier integrity. Butyrate receptors are also highly expressed throughout the body, especially on immune and endocrine cells [
148]. Thus, it is possible that reduced butyrate production may contribute to the impaired gut barrier permeability and subsequent bacterial translocation into the systemic circulation, alongside systemic inflammation, that have been implicated [
150] in, and observed [
151] in mental disorders. Importantly, high fibre dietary interventions that have already demonstrated efficacy in improving outcomes in moderate to severe MDD [
32] also increase butyrate-producing bacteria [
152].
Our review also indicated that there were higher levels of bacteria associated with the metabolism of glutamate and γ-aminobutyric acid (GABA) across all three mental disorders. Again, there was very little evidence to suggest this pattern was particularly associated with any specific disorder, with higher
Lactobacillus a common feature across all disorders. Higher abundances of
Alistipes and
Parabacteroides were a feature of MDD, higher
Bifidobacterium a feature of BD, higher
Enterococcus a feature of both MDD and BD and lower
Bacteroides and
Streptococcus a feature of SZ; these bacteria are associated with glutamate and GABA metabolism.
The previously mentioned lactic acid-producing bacteria
Lactobacillus,
Bifidobacterium and
Enterococcus contain genes encoding glutamate decarboxylase (GAD) enzymes, which catalyse the reaction of L-glutamate to GABA [
153,
154].
Eggerthella species are less commonly studied, however may also influence glutamate metabolism via GAD, and higher levels of
Eggerthella have been associated with changes in glutamate metabolism in children with autism spectrum disorder [
155]. In addition,
Bacteroides,
Escherichia and
Parabacteroides have also been associated with GABA production [
156]. It is possible that these gut bacteria observed in higher abundances across mental disorders may facilitate greater utilisation of glutamate (i.e. depletion) and increased synthesis of GABA.
The pathophysiological implications of differential abundances of specific bacteria remains to be confirmed. This highlights the need for multi-omics approaches to better understand the dynamic and complex functionality of the human gut microbiota. In addition, whether gut microbiota differences are the cause or consequence of pathophysiology, or are jointly influenced by shared risk factors such as diet, requires further exploration. Future longitudinal cohort studies will afford the documentation of changes in the gut microbiota and their relationship to disease development and may help to determine causality. Finally, intervention studies may help to further elucidate the mechanistic and biochemical implications of specific bacterial taxa on host health and disease.
1: How much does the fecal-transplantation thing tend to cost?
2: If you get the fecal-transplantation thing done but then you mess up your microbiota again then you're screwed, right? It seems like there would be unbelievable pressure to live an ultra-healthy lifestyle (regarding diet, exercise, etc., etc.). I'm not sure how resilient the new microbiota would be; normal people aren't plunged into horrifying dysbiosis whenever they're a bit unhealthy, so hopefully the patient who got the fecal-transplantation thing done wouldn't have to worry.
3: To what extent does the fecal-transplantation thing ever "stick"? The patient will have to eat extremely (!!!) carefully and exercise and do everything in a way that protects the new gut microbiota from any threats, correct? And furthermore, there might be genetic aspects of the patient that contributed to the patient having messed-up gut microbiota in the first place; these genetic threats will persist after the transplantation has been done, of course, so isn't that a major problem?
4: See below on the cost of the fecal-transplantation thing:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023044/
Recent studies have looked at the cost-effectiveness of FMT when compared to antibiotic drugs for the treatment of hospital-acquired
C. difficile infection (CDI). One study in Canada used a Markov model to simulate a 65-year-old patient with second recurrence of mild-to-moderate CDI. They compared treatment options in areas with FMT programs and without an established program. After analysis and conversion to US dollars, outpatient vancomycin was $419.05 per course of treatment and fidaxomicin, brand name Dificid, was $1552.88 per course of treatment. FMT via capsule was $2097.39 [
18]. Vancomycin and fidaxomicin are common first-line therapies for CDI and have a high potential for recurrence, which is shown in the study for probability of success in curing CDI. Vancomycin had a success rate of 0.556 and fidaxomicin had a success rate of 0.710, while FMT’s lowest success rate was 0.898 with capsule transmission of the healthy gut bacteria [
18]. The total cost of FMT, including all aspects of treatment like screening and prep of the sample, was estimated at $3510.26 when compared to the use and prep of vancomycin and $3422.43 when compared to the use and prep of fidaxomicin. This cost is for FMT via colonoscopy, which was the highest cost estimated for FMT, and the number to treat to be comparable to antibiotics was 15 and 16, respectively. These costs seem to be more than what is currently available for patients and less cost-effective overall. One aspect to consider when comparing cost is hospitalization for patients with recurring CDI, which is a common occurrence with CDI after treatment with antibiotics. Hospitalization cost was checked during the study mentioned above. The cost for hospitalization due to mild-to-moderate recurrent CDI was $2688.94, $5252.99 for severe CDI that does not require a colectomy, and $17,082.18 for severe CDI that did require a colectomy [
18]. Another U.S. study performed a similar study using a Markov model of a 67-year-old patient and found that success rates of vancomycin and fidaxomicin were higher at 0.846 and 0.800 for severe infections, respectively [
19]. FMT may currently have higher costs that can be lowered over time, like screenings that are at a current cost of $883.60, but treatment of patients with pharmaceuticals that have less than 75% success rates may lead to worsening patient outcomes, increased mortality rates, and overall higher cost due to hospitalization of these patients [
19].